Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2507955122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Alexandra C Willcox und 10 weiteren Autor:innen. Beteiligte Einrichtung: Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109. Hauptthemen laut MEDLINE: Zika Virus, Interferon Type I, Zika Virus Infection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Zika virus (ZIKV) has caused multiple human outbreaks, with more recent epidemics associated with severe outcomes in infants. Today, ZIKV is endemic to many countries and presents a persistent threat for future epidemics. The host innate immune proteins that regulate ZIKV replication are incompletely defined. We developed a CRISPR knockout screen to identify host factors that impact ZIKV replication, resulting in the finding of angiomotin-like protein 2 (AMOTL2), a protein that inhibits ZIKV by regulating the host type I interferon (IFN) response. AMOTL2 affects IFN signaling by modulating STAT1 levels and activation in response to type I IFN. Thus, AMOTL2, which has largely been studied for its role in cancer, represents an antiviral protein that interacts with the IFN signaling pathway to promote downstream expression of IFN stimulated genes, resulting in restriction of ZIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
- Medical Scientist Training Program, University of Washington, Seattle, WA 98195.
- Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98195.
- Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
- Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Willcox, A. C., Gobillot, T. A., Kikawa, C., Baumgarten, N. E., Stoddard, C. I., Sung, K., Bhattacharya, T., Freeman, T. S., Marceau, J., Humes, D., & Overbaugh, J. (2025). Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2507955122
Vancouver
Willcox AC, Gobillot TA, Kikawa C, Baumgarten NE, Stoddard CI, Sung K, et al. Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2507955122
BibTeX
@article{Willcox2025,
author = {Willcox, Alexandra C and Gobillot, Theodore A and Kikawa, Caroline and Baumgarten, Nell E and Stoddard, Caitlin I and Sung, Kevin and Bhattacharya, Tamanash and Freeman, Tiia S and Marceau, Joshua and Humes, Daryl and Overbaugh, Julie},
title = {Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2507955122}
}
EUVIMED